NCT07226726 Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
| NCT ID | NCT07226726 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | The Foundation for Orthopaedics and Regenerative Medicine |
| Condition | Congenital Myasthenic Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2025-01-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
Eligibility Criteria
Inclusion Criteria: * Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician. * Patients must be able to provide informed consent, or have a guardian who does. * Patient must be able to travel to the site of treatment. Exclusion Criteria: * Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07226726 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Congenital Myasthenic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07226726 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07226726 currently recruiting?
Yes, NCT07226726 is actively recruiting participants. Contact the research team at care@thepsci.com for enrollment information.
Where is the NCT07226726 trial being conducted?
This trial is being conducted at Naples, United States, Irving, United States, St John's, Antigua and Barbuda.
Who is sponsoring the NCT07226726 clinical trial?
NCT07226726 is sponsored by The Foundation for Orthopaedics and Regenerative Medicine. The trial plans to enroll 20 participants.